Global Blepharitis Market expected to hit USD 14.62 Bn by 2029 from USD 10.89 Bn in 2022 at a CAGR of 4.3% during the forecast periodBlepharitis Market Overview
Blepharitis is an inflammation of the free edge of the eyelid which can spread to all eyelids. Blepharitis manifests itself by redness and swelling of the eyelid, with small scabs on the skin and at the root of the eyelashes. It often affects both eyes at the same time and causes pain or itching of the eyelids. This usually happens due to bacteria on the skin. Blepharitis is present in 11 to 25 percent population of the world. This majorly attacks on the geriatric population due to less immunity as compared to their age. To know about the Research Methodology :- Request Free Sample ReportBlepharitis Market Dynamics
Market Drivers The rising incidence of Blepharitis, a chronic inflammatory condition of the eyelids and the growing cases of blepharitis across the world are expected to drive the Blepharitis Market. The factors such as age, poor eyelid hygiene and having too much bacteria near the base of your eyelashes and various environmental conditions are also contributing to the increasing cases of this condition. The major Blepharitis Key Companies are constantly working on developing preservative-free lubricant eye drops, anti-inflammatory drugs and liquid drops to provide instant relief for blepharitis. Increased awareness among individuals and healthcare personnel regarding the symptoms and seriousness of blepharitis is expected to help in early diagnosis and treatment. Most people ignore symptoms of blepharitis since it usually does not cause permanent damage to the eyesight and it is not also contagious. But blepharitis often led to a chronic condition, which is difficult to treat. All these factors are expected to drive the Global Blepharitis Market Growth. The blepharitis prevalence is relatively high in the United States as compared to other parts of the world. The major Blepharitis Key Players have their research centers in the United States. The research suggests that blepharitis affects adults and children of both sexes equally and the staphylococcal form of blepharitis mainly affects women. The advancements in medical Distribution Channels such as diagnostic tools and treatment options are expected to improve the management of blepharitis condition. The latest devices and instruments for diagnosis coupled with innovative therapies are expected to boost the Blepharitis Market. Also, vitamin D deficiency and meibomian gland dysfunction (MGD) are the most common causes of dry eye symptoms and affect about 75 percent of people with serious blepharitis. All these factors are expected to propel the growth of the Blepharitis Industry and increase the Blepharitis Market Size respectively. Blepharitis is more common in older adults. With the global aging population, there is a significant increase in the number of individuals susceptible to this condition. The growing geriatric population and the increasing cases of blepharitis in this age group act as the major factors driving the Blepharitis Market. There is a rising demand for over-the-counter (OTC) products and self-care solutions for managing Blepharitis symptoms. These OTC medicines relieve aches, pains, and itches. Some prevent or cure diseases such as blepharitis. People try to avoid visiting health clinics for the small cause since the trend and demand for drugs without a prescription is growing over the period of time. These include eyelid cleansers, warm compresses, and artificial tears. The convenience and accessibility of OTC products are expected to drive Blepharitis Market. The Blepharitis Market growth is supported by the ongoing research and development activities in the field of Blepharitis and pharmaceutical companies and academic institutions are investing in developing novel therapies, targeted drug delivery systems and innovative formulations to improve the management of Blepharitis. The introduction of new treatment options and advancements in existing therapies propel market growth and attract attention from healthcare providers and patients. Blepharitis Market Restraints The report analyzes the Blepharitis Market Data through SWOT analysis and PORTER’s five force model, which provides information about drivers, restraints, opportunities and regional opportunities to assist new Blepharitis Key Players in the Blepharitis Medical Industry. The factors such as limited awareness and lack of standardized diagnostic criteria and uncertain treatment guidelines are expected to limit the growth of the Blepharitis Market. The affordable and effective treatment options are limited and also the lack of skilled personnel and fragmented condition of the market and disruptions happened in the medical industry are also expected to impede the growth of the market.Blepharitis Market Regional Insights
North America held the largest share in the Blepharitis Market and is expected to dominate throughout the forecast period (2023-2029). Blepharitis is the most common ocular disorder and over 82 million people in the United States are affected by blepharitis. Recent years have brought several improvements in the treatment of blepharitis. The United States spends the largest amount on healthcare development, which is the highest in the world and also funds research organizations and institutes for the improvement and launch of new drugs and solutions. These all factors are expected to boost North America Blepharitis Industry. The market growth is also supported by the presence of major Blepharitis Key Players in the region. Among them, Bausch+Lomb and Novaliq announced the submission of a new drug Drug for the investigational treatment perfluorohexyloctane (NOV03). This is the first drug developed to treat blepharitis associated with meibomian gland dysfunction in a highly effective way. These research and developments are expected to propel the growth of the key companies’ Blepharitis Market share and Blepharitis Market Size. Europe’s Blepharitis Market is expected to grow at the highest CAGR of 5.7 percent during the forecast period. The growing incidence of blepharitis and ocular pains due to infections, foreign objects, dirt and dust in the region is expected to drive the Blepharitis Industry. Blepharitis usually occurs in the cold and windy atmosphere and Europe’s climate is always exposed to winter, which increases the prevalence of blepharitis in the region. These factors are expected to drive the region’s Blepharitis Drug Industry. Asia Pacific is a growing market to invest in for major Blepharitis Key Companies to increase their Blepharitis Market Share in the Blepharitis Industry. The factors such as growth in the population, rising health awareness and increasing population are expected to drive the region’s market. Also, the growing rate of pharmaceutical companies and biotech labs in China and the existing Blepharitis Key Players in India such as Serum Institute and Waypham are constantly providing complete eye health management starting from better patient awareness, preventive measures, improved Eye Hygiene habits, and Eye Nutrition. These factors are expected to increase the Blepharitis Key Companies in the region due to growing opportunities.Blepharitis Market Competitive Landscape
The report provides Blepharitis Market Competitive Benchmarking through Blepharitis Market Size, Share and Revenue of major B lepharitis Key Companies. Scope Ophthalmic Ltd., Novartis AG, InSite Vision Incorporated and Thea Pharmaceuticals, Inc. are some of the major Blepharitis Key Players in the Blepharitis Industry. Recently on January 17, 2023, Bausch+Lomb acquired AcuFocus, Inc. This is expected to focus on areas of unmet medical need that the organization believe is expected to help in driving long-term growth in core segments and to achieve the mission of helping people see better to live better. This acquisition is expected to drive the growth of the Blepharitis Market during the forecast period. Also, on April 4, 2022, Thea Pharmaceuticals, Inc. introduced iVIZIA OTC eye care products that include eye drops, lubricating eye gel and three options for daily hygiene of sensitive eyelids. iVIZIA eye drops offer preservative-free extended relief and ocular surface protection to patients with any type of dry eye, including those who wear contact lenses. The eye drops are delivered in a patented multidose bottle developed by Théa that protects against contamination while reliably dispensing only one dose-calibrated drop at a time to prevent the nuisance and waste caused by the streaming of drops experienced with other multidose bottles. These developments by the Blepharitis Key Companies are expected to drive the Blepharitis Market globally.Blepharitis Market Segment Analysis
Based on Drug The lubricant eye drops segment is expected to hold the largest revenue share in the Blepharitis Market. The preservative-free eye drops don’t get contaminated with pathogens between uses and calm the surface of the eye and lubricate the eye surface and cure dry eyes. Preservative-free eye drops are becoming widely available. Early research indicates that they are expected to be more effective at lubricating and protecting your eyes. The oily tear eye drops help in improving symptoms of dry eye or blepharitis. The oily eye drops have antimicrobial and anti-inflammatory properties that make them safe for the eyes and boost tear film lipids. Oily drops are a source of biodegradable polymers, cosmetics, lubricants, adhesives, coatings, and more. It’s also used in medicine, pharmaceuticals, and biorefineries. These factors are expected to increase the Blepharitis Market Revenue Share of the segment. Based on Product The liquid drop segment is expected to grow significantly through the forecast period (2023-2029). Liquid eye drops increase the eye’s natural moisture when the eyes are not making enough on their own. They relieve dryness and irritation, promoting comfort. These liquid drops prevent expected damage by keeping the eye lubricated. Due to these factors liquid eye drops are being widely used in the treatment of blepharitis. This is expected to drive the segment in the Global Blepharitis Market. Based on Distribution Channel The pharmacies segment is expected to hold a large revenue share in the Blepharitis Market throughout the forecast period. The pharmacies work in coordination with doctors and ensure patients take their medicines on time. The prescribed medicines are only distributed through the pharmacies and they work as a community and guide on the right dosage of drugs. Due to these factors pharmacies segment is expected to hold the largest share of the Blepharitis Market.Blepharitis Market Scope: Inquire before buying
Blepharitis Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: USD 10.89 Bn Forecast Period 2023 to 2029 CAGR: 4.3% Market Size in 2029: USD 14.62 Bn Segments Covered: by Drug 1. Lubricant Eye Drops 1.2 Preservative-free Drops 1.3 Oily Tear Eye Drops 2 Anti-inflammatory Drugs 2.1 Corticosteroid 2.2 Tetracyclines Oral 3 Autologous Serum Eye Drops by Product 1. Liquid Drops 2. Gel 3. Liquid Wipes 4. Eye Ointment 5. Other by Distribution Channel 1. Pharmacies 2. Drug Store 3. Supermarkets 4. E-commerce Blepharitis Market, by Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Blepharitis Key Players include:
1. Scope Ophthalmic Ltd. 2. Novartis AG 3. InSite Vision Incorporated 4. Thea Pharmaceuticals, Inc 5. Merck & Co. 6. Perrigo Laboratories 7. Kala Pharmaceuticals 8. AbbVie Inc. 9. Amgen Inc. 10.Biogen Inc. 11.Celgene Corporation 12.Pfizer Inc. 13.Regeneron Pharmaceuticals, Inc. 14.Gilead Sciences, Inc. 15.Johnson & Johnson 16.NovaBay Pharmaceuticals 17.Foamix, Ltd. 18.Gelderma S.A. 19.Lux Biosciences, Inc. Frequently Asked Questions: 1] What is the growth rate of the Blepharitis Market? Ans. The Blepharitis Market is growing at a CAGR of 4.3% during the forecast period. 2] Which region is expected to dominate the Blepharitis Market? Ans. North America is expected to dominate the Blepharitis Market during the forecast period from 2023 to 2029. 3] What is the expected Blepharitis Market size by 2029? Ans. The size of the Blepharitis Market by 2029 is expected to reach USD 14.62 Bn. 4] Who are the top players in the Blepharitis Market? Ans. The major key players in the Blepharitis Market are Scope Ophthalmic Ltd., Novartis AG and InSite Vision Incorporated and Thea Pharmaceuticals, Inc 5] Which factors contributed to the growth of the Blepharitis Market in 2022? Ans. The Blepharitis Market is expected to grow due to the rising prevalence of blepharitis and growing awareness.
1. Blepharitis Market: Research Methodology 2. Blepharitis Market: Executive Summary 3. Blepharitis Market: Competitive Landscape 3.1. MMR Competition Matrix 3.2. Competitive Landscape 3.3. Key Players Benchmarking 3.4. Market Structure 3.4.1. Market Leaders 3.4.2. Market Followers 3.4.3. Emerging Players 3.5. Consolidation of the Market 4. Blepharitis Market: Dynamics 4.1. Market Trends by region 4.1.1. North America 4.1.2. Europe 4.1.3. Asia Pacific 4.1.4. Middle East and Africa 4.1.5. South America 4.2. Market Drivers by Region 4.2.1. North America 4.2.2. Europe 4.2.3. Asia Pacific 4.2.4. Middle East and Africa 4.2.5. South America 4.3. Market Restraints 4.4. Market Opportunities 4.5. Market Challenges 4.6. PORTER’s Five Forces Analysis 4.7. PESTLE Analysis 4.8. Value Chain Analysis 4.9. Regulatory Landscape by Region 4.9.1. North America 4.9.2. Europe 4.9.3. Asia Pacific 4.9.4. Middle East and Africa 4.9.5. South America 5. Blepharitis Market: Segmentation (by Value USD and Volume Units) 5.1. Blepharitis Market, by Drug (2022-2029) 5.1.1. Lubricant Eye Drops 5.1.1.1. Preservative-free Drops 5.1.1.2. Oily Tear Eye Drops 5.1.2. Anti-inflammatory Drugs 5.1.2.1. Corticosteroid 5.1.2.2. Tetracyclines Oral 5.1.3. Autologous Serum Eye Drops 5.2. Blepharitis Market, by Product (2022-2029) 5.2.1. Liquid Drops 5.2.2. Gel 5.2.3. Liquid Wipes 5.2.4. Eye Ointment 5.2.5. Other 5.3. Blepharitis Market, by Distribution Channel (2022-2029) 5.3.1. Pharmacies 5.3.2. Drug Store 5.3.3. Supermarkets 5.3.4. E-commerce 5.4. Blepharitis Market, by Region (2022-2029) 5.4.1. North America 5.4.2. Europe 5.4.3. Asia Pacific 5.4.4. Middle East and Africa 5.4.5. South America 6. North America Blepharitis Market (by Value USD and Volume Units) 6.1. North America Blepharitis Market, by Drug (2022-2029) 6.1.1. Lubricant Eye Drops 6.1.1.1. Preservative-free Drops 6.1.1.2. Oily Tear Eye Drops 6.1.2. Anti-inflammatory Drugs 6.1.2.1. Corticosteroid 6.1.2.2. Tetracyclines Oral 6.2. North America Blepharitis Market, by Product (2022-2029) 6.2.1. Liquid Drops 6.2.2. Gel 6.2.3. Liquid Wipes 6.2.4. Eye Ointment 6.2.5. Other 6.3. North America Blepharitis Market, by Distribution Channel (2022-2029) 6.3.1. Pharmacies 6.3.2. Drug Store 6.3.3. Supermarkets 6.3.4. E-commerce 6.4. North America Blepharitis Market, by Country (2022-2029) 6.4.1. United States 6.4.2. Canada 6.4.3. Mexico 7. Europe Blepharitis Market (by Value USD and Volume Units) 7.1. Europe Blepharitis Market, by Drug (2022-2029) 7.2. Europe Blepharitis Market, by Product (2022-2029) 7.3. Europe Blepharitis Market, by Distribution Channel (2022-2029) 7.4. Europe Blepharitis Market, by Country (2022-2029) 7.4.1. UK 7.4.2. France 7.4.3. Germany 7.4.4. Italy 7.4.5. Spain 7.4.6. Sweden 7.4.7. Austria 7.4.8. Rest of Europe 8. Asia Pacific Blepharitis Market (by Value USD and Volume Units) 8.1. Asia Pacific Blepharitis Market, by Drug (2022-2029) 8.2. Asia Pacific Blepharitis Market, by Product (2022-2029) 8.3. Asia Pacific Blepharitis Market, by Distribution Channel (2022-2029) 8.4. Asia Pacific Blepharitis Market, by Country (2022-2029) 8.4.1. China 8.4.2. S Korea 8.4.3. Japan 8.4.4. India 8.4.5. Australia 8.4.6. Indonesia 8.4.7. Malaysia 8.4.8. Vietnam 8.4.9. Taiwan 8.4.10. Bangladesh 8.4.11. Pakistan 8.4.12. Rest of Asia Pacific 9. Middle East and Africa Blepharitis Market (by Value USD and Volume Units) 9.1. Middle East and Africa Blepharitis Market, by Drug (2022-2029) 9.2. Middle East and Africa Blepharitis Market, by Product (2022-2029) 9.3. Middle East and Africa Blepharitis Market, by Distribution Channel (2022-2029) 9.4. Middle East and Africa Blepharitis Market, by Country (2022-2029) 9.4.1. South Africa 9.4.2. GCC 9.4.3. Egypt 9.4.4. Nigeria 9.4.5. Rest of ME&A 10. South America Blepharitis Market (by Value USD and Volume Units) 10.1. South America Blepharitis Market, by Drug (2022-2029) 10.2. South America Blepharitis Market, by Product (2022-2029) 10.3. South America Blepharitis Market, by Distribution Channel (2022-2029) 10.4. South America Blepharitis Market, by Country (2022-2029) 10.4.1. Brazil 10.4.2. Argentina 10.4.3. Rest of South America 11. Company Profile: Key players 11.1. Scope Ophthalmic Ltd. 11.1.1. Company Overview 11.1.2. Financial Overview 11.1.3. Business Portfolio 11.1.4. SWOT Analysis 11.1.5. Business Strategy 11.1.6. Recent Developments 11.2. Novartis AG 11.3. InSite Vision Incorporated 11.4. Thea Pharmaceuticals, Inc 11.5. Merck & Co. 11.6. Perrigo Laboratories 11.7. Kala Pharmaceuticals 11.8. AbbVie Inc. 11.9. Amgen Inc. 11.10. Biogen Inc. 11.11. Celgene Corporation 11.12. Pfizer Inc. 11.13. Regeneron Pharmaceuticals, Inc. 11.14. Gilead Sciences, Inc. 11.15. Johnson & Johnson 11.16. NovaBay Pharmaceuticals 11.17. Foamix, Ltd. 11.18. Gelderma S.A. 11.19. Lux Biosciences, Inc. 12. Key Findings 13. Industry Recommendation